Long-Term Remission in Ph-Negative B-ALL With Sequential CAR T, ASCT
Patients achieve a high 2-year survival and deep MRD-negative remissions with CAR T-cell therapy followed by stem cell transplant in B-cell ALL.
FDA Grants Breakthrough Therapy Designation to R-DXd in CDH6-Expressing Ovarian Cancer
Raludotatug deruxtecan (R-DXd) earned FDA breakthrough designation for CDH6-expressing platinum-resistant ovarian cancers after bevacizumab (Avastin; Genentech) treatment.
